Cargando…

Effect of oral intake of royal jelly on endothelium function in hemodialysis patients: study protocol for multicenter, double-blind, randomized control trial

BACKGROUND: Hemodialysis (HD) is a common renal replacement therapy for patients with renal failure. Cardiovascular and cerebrovascular diseases are known to shorten survival periods and worsen the quality of life of HD patients. Atherosclerosis is a major cause of vascular diseases, and various fac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohba, Kojiro, Miyata, Yasuyoshi, Shinzato, Takeaki, Funakoshi, Satoshi, Maeda, Kanenori, Matsuo, Tomohiro, Mitsunari, Kensuke, Mochizuki, Yasushi, Nishino, Tomoya, Sakai, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690339/ https://www.ncbi.nlm.nih.gov/pubmed/34930416 http://dx.doi.org/10.1186/s13063-021-05926-x

Ejemplares similares

Mechanisms Underlying the Inhibition of Tyrosine Kinase Inhibitor-Induced Anorexia and Fatigue by Royal Jelly in Renal Cell Carcinoma Patients and the Correlation between Macrophage Colony Stimulating Factor and Inflammatory Mediators
por: Yuno, Tsutomu, et al.
Publicado: (2020)

Left atrial metastasis of renal cell carcinoma: a case report and review of the literature
por: Ohba, Kojiro, et al.
Publicado: (2014)

Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial
por: Araki, Kyohei, et al.
Publicado: (2018)

Correction: Oral Intake of Royal Jelly Has Protective Effects against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial. Medicines, 2019, 6, 2
por: Araki, Kyohei, et al.
Publicado: (2020)

Met in Urological Cancers
por: Miyata, Yasuyoshi, et al.
Publicado: (2014)

Periodontal Disease in Patients Receiving Dialysis
por: Miyata, Yasuyoshi, et al.
Publicado: (2019)

Pathological Characteristics of Periodontal Disease in Patients with Chronic Kidney Disease and Kidney Transplantation
por: Kitamura, Mineaki, et al.
Publicado: (2019)

Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants
por: Miyata, Yasuyoshi, et al.
Publicado: (2019)

Pathological Significance of Macrophages in Erectile Dysfunction Including Peyronie’s Disease
por: Miyata, Yasuyoshi, et al.
Publicado: (2021)

Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial
por: Miyata, Yasuyoshi, et al.
Publicado: (2020)

Oral intake of royal jelly improves anti-cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF-α and TGF-β in renal cell carcinoma: A preliminary study based on a randomized double-blind clinical trial
por: Miyata, Yasuyoshi, et al.
Publicado: (2020)

Relationship between Urinary Calcium Excretion and Lower Urinary Tract Symptoms
por: Matsuo, Tomohiro, et al.
Publicado: (2022)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
por: Ito, Hidenori, et al.
Publicado: (2022)

Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake
por: Matsuo, Tomohiro, et al.
Publicado: (2021)

Excessive accumulation of visceral fat is associated with lower urinary symptoms including overactive bladder in female patients
por: Otsubo, Asato, et al.
Publicado: (2020)

Presurgical bladder wall thickness is a useful marker to predict the postsurgical improvement of symptoms in patients with pelvic organ prolapse‐related overactive bladder
por: Otsubo, Asato, et al.
Publicado: (2021)

High Expression of HuR in Cytoplasm, but Not Nuclei, Is Associated with Malignant Aggressiveness and Prognosis in Bladder Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2013)

Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers
por: Miyata, Yasuyoshi, et al.
Publicado: (2020)

Recovery from life-threatening pelvic organ prolapse in an 80-year-old Japanese woman: a case report
por: Matsuo, Tomohiro, et al.
Publicado: (2014)

Anti-Cancer and Protective Effects of Royal Jelly for Therapy-Induced Toxicities in Malignancies
por: Miyata, Yasuyoshi, et al.
Publicado: (2018)

Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1
por: Mukae, Yuta, et al.
Publicado: (2020)

Present Status, Limitations and Future Directions of Treatment Strategies Using Fucoidan-Based Therapies in Bladder Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2020)

Pharmacological Effects and Potential Clinical Usefulness of Polyphenols in Benign Prostatic Hyperplasia
por: Mitsunari, Kensuke, et al.
Publicado: (2021)

Pathological significance and prognostic role of LATS2 in prostate cancer
por: Matsuda, Tsuyoshi, et al.
Publicado: (2021)

Molecular Mechanisms of the Anti-Cancer Effects of Isothiocyanates from Cruciferous Vegetables in Bladder Cancer
por: Mastuo, Tomhiro, et al.
Publicado: (2020)

A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis
por: Miyata, Yasuyoshi, et al.
Publicado: (2017)

Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non‐muscle‐invasive bladder cancer: a randomised clinical trial
por: Miyata, Yasuyoshi, et al.
Publicado: (2021)

Oral administration of E-type prostanoid (EP) 1 receptor antagonist suppresses carcinogenesis and development of prostate cancer via upregulation of apoptosis in an animal model
por: Masato, Masahito, et al.
Publicado: (2021)

Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis
por: Miyata, Yasuyoshi, et al.
Publicado: (2012)

The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men
por: Matsuo, Tomohiro, et al.
Publicado: (2016)

Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo‐Adjuvant Hormonal Therapy in Prostate Cancer Patients
por: Asai, Akihiro, et al.
Publicado: (2016)

Anticancer Effects of Green Tea and the Underlying Molecular Mechanisms in Bladder Cancer
por: Miyata, Yasuyoshi, et al.
Publicado: (2018)

Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder
por: Matsuo, Tomohiro, et al.
Publicado: (2019)

Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy
por: Miyata, Yasuyoshi, et al.
Publicado: (2015)

Neoadjuvant hormonal therapy for low‐risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis‐related parameters
por: Miyata, Yasuyoshi, et al.
Publicado: (2017)

A pilot study to assess the safety and usefulness of combined transurethral endoscopic mucosal resection and en-bloc resection for non-muscle invasive bladder cancer
por: Hayashida, Yasushi, et al.
Publicado: (2019)

The Relationship between the Presence of an Earlobe Crease and Overactive Bladder: A Cross-Sectional Case-Controlled Study
por: Ueda, Yasufumi, et al.
Publicado: (2023)

CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34
por: Miyata, Yasuyoshi, et al.
Publicado: (2013)

Evans syndrome during pembrolizumab therapy for upper urinary tract cancer
por: Kakita, Shota, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d8k1vajhlahde33vv0h2bm11gk